Regulator waives off clinical trials, clears Sanofi TB Drug

“We have recently received final approval for rifapentine from the Indian regulatory authorities. Rifapentine is now officially registered in India,” Thibaud Lefort, Sanofi’s global health business chief, told ET on the sidelines of the 50th Union World Conference of Lung Health in Hyderabad.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/32ju5Pa
via IFTTT